Dupilumab Treatment improves QoL in Adult Patients with Moderate-to-Severe Atopic Dermatitis
Mean QoLIAD scores at baseline were 13.3 (±1.34) and 11.3 (±1.09) for the placebo and dupilumab group, respectively. Dupilumab significantly improved QoLIAD score after 12 weeks of treatment vs. placebo. LS mean % difference from baseline vs. placebo in QoLIAD score (±SE) was −52.0 (±11.43; P<0.0001). QoLIAD scores significantly correlated with changes in efficacy outcomes, including EASI (r=0.4355), 5-dimensional pruritus (r=0.4937), pruritus NRS (r=0.4064), total SCORAD (r=0.5559), and SCORAD VAS scores for sleep (r=0.4681) and pruritus (r=0.5400); all P<0.05.
The findings thus show dupilumabto have an improvement in QoLIAD scores in adults with AD and to be significantly associated with improvements in study outcomes. These findings should make it easy to carry forward a largescale phase III study.